IMPROVING OUTCOMES FOR WOMEN WITH EPITHELIAL OVARIAN CANCER
Grant number: 1092856 | Funding period: 2016 - 2021
Related publications (23)
Multiomic analysis of homologous recombination-deficient end-stage high-grade serous ovarian cancer.
Nikki L Burdett, Madelynne O Willis, Kathryn Alsop, Allison L Hunt, Ahwan Pandey, Phineas T Hamilton, Tamara Abulez, Xuan Liu, Therese Hoang, Stuart Craig, Sian Fereday, Joy Hendley, Dale W Garsed, Katy Milne, Shreena Kalaria, Ashley Marshall, Brian L Hood, Katlin N Wilson, Kelly A Conrads, Kathleen I Pishas
High-grade serous ovarian cancer (HGSC) is frequently characterized by homologous recombination (HR) DNA repair deficiency and, wh..
Older age should not be a barrier to testing for somatic variants in homologous recombination DNA repair-related genes in patients with high-grade serous ovarian carcinoma.
Omali Pitiyarachchi, Yeh Chen Lee, Hao-Wen Sim, Sivatharsny Srirangan, Cristina Mapagu, Judy Kirk, Paul R Harnett, Rosemary L Balleine, David DL Bowtell, Goli Samimi, Alison H Brand, Deborah J Marsh, Philip Beale, Lyndal Anderson, Natalie Bouantoun, Pamela Provan, null INOVATe Investigators, Susan J Ramus, Anna DeFazio, Michael Friedlander
BACKGROUND: Somatic pathogenic variants (PVs) in homologous recombination DNA repair (HR)-related genes found in high-grade serous..
Increased FOXJ1 protein expression is associated with improved overall survival in high-grade serous ovarian carcinoma: an Ovarian Tumor Tissue Analysis Consortium Study.
Ashley Weir, Eun-Young Kang, Nicola S Meagher, Gregg S Nelson, Prafull Ghatage, Cheng-Han Lee, Marjorie J Riggan, Aleksandra Gentry-Maharaj, Andy Ryan, Naveena Singh, Martin Widschwendter, Jennifer Alsop, Michael S Anglesio, Matthias W Beckmann, Jessica Berger, Christiani Bisinotto, Jessica Boros, Alison H Brand, James D Brenton, Angela Brooks-Wilson
BACKGROUND: Recently, we showed a >60% difference in 5-year survival for patients with tubo-ovarian high-grade serous carcinoma (H..
Profiling the immune landscape in mucinous ovarian carcinoma.
Nicola S Meagher, Phineas Hamilton, Katy Milne, Shelby Thornton, Bronwyn Harris, Ashley Weir, Jennifer Alsop, Christiani Bisinoto, James D Brenton, Angela Brooks-Wilson, Derek S Chiu, Kara L Cushing-Haugen, Sian Fereday, Dale W Garsed, Simon A Gayther, Aleksandra Gentry-Maharaj, Blake Gilks, Mercedes Jimenez-Linan, Catherine J Kennedy, Nhu D Le
OBJECTIVE: Mucinous ovarian carcinoma (MOC) is a rare histotype of ovarian cancer, with low response rates to standard chemotherap..
Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes
Nicola S Meagher, Kylie L Gorringe, Matthew Wakefield, Adelyn Bolithon, Chi Nam Ignatius Pang, Derek S Chiu, Michael S Anglesio, Kylie-Ann Mallitt, Jennifer A Doherty, Holly R Harris, Joellen M Schildkraut, Andrew Berchuck, Kara L Cushing-Haugen, Ksenia Chezar, Angela Chou, Adeline Tan, Jennifer Alsop, Ellen Barlow, Matthias W Beckmann, Jessica Boros
PURPOSE: Advanced-stage mucinous ovarian carcinoma (MOC) has poor chemotherapy response and prognosis and lacks biomarkers to aid ..
The genomic and immune landscape of long-term survivors of high-grade serous ovarian cancer
Dale W Garsed, Ahwan Pandey, Sian Fereday, Catherine J Kennedy, Kazuaki Takahashi, Kathryn Alsop, Phineas T Hamilton, Joy Hendley, Yoke-Eng Chiew, Nadia Traficante, Pamela Provan, Dinuka Ariyaratne, George Au-Yeung, Nicholas W Bateman, Leanne Bowes, Alison Brand, Elizabeth L Christie, Julie M Cunningham, Michael Friedlander, Bronwyn Grout
Fewer than half of all patients with advanced-stage high-grade serous ovarian cancers (HGSCs) survive more than five years after d..
High Prediagnosis Inflammation-Related Risk Score Associated with Decreased Ovarian Cancer Survival
Katharine K Brieger, Minh Tung Phung, Bhramar Mukherjee, Kelly M Bakulski, Hoda Anton-Culver, Elisa Bandera, David DL Bowtell, Daniel W Cramer, Anna DeFazio, Jennifer A Doherty, Sian Fereday, Renee Turzanski Fortner, Aleksandra Gentry-Maharaj, Ellen L Goode, Marc T Goodman, Holly R Harris, Keitaro Matsuo, Usha Menon, Francesmary Modugno, Kirsten B Moysich
BACKGROUND: There is suggestive evidence that inflammation is related to ovarian cancer survival. However, more research is needed..
Evolution of core archetypal phenotypes in progressive high grade serous ovarian cancer.
Aritro Nath, Patrick Cosgrove, Benjamin Copeland, Hoda Mirsafian, Elizabeth Christie, Lance Pflieger, Sumana Majumdar, Mihaela Cristea, Ernest Han, Stephen Lee, Edward Wang, Sian Fereday, Nadia Traficante, Ravi Salgia, Theresa Werner, Adam Cohen, Phillip Moos, Jeffrey Chang, David Bowtell, Andrea Bild
The evolution of resistance in high-grade serous ovarian cancer (HGSOC) cells following chemotherapy is only partially understood...
Oncologists' perspectives of telephone genetic counseling to facilitate germline BRCA1/2 testing for their patients with high-grade serous ovarian cancer
Pierre Hemming, Rajneesh Kaur, Bettina Meiser, Joanne McKinley, Mary-Anne Young, Paul A James, Laura E Forrest
Poly ADP ribose polymerase (PARP) inhibitors offer a survival advantage to women with high-grade serous ovarian cancer who have a ..
Genomic analysis of low-grade serous ovarian carcinoma to identify key drivers and therapeutic vulnerabilities
Dane Cheasley, Abhimanyu Nigam, Magnus Zethoven, Sally Hunter, Dariush Etemadmoghadam, Timothy Semple, Prue Allan, Mark S Carey, Marta L Fernandez, Amy Dawson, Martin Kobel, David G Huntsman, Cecile Le Page, Anne-Marie Mes-Masson, Diane Provencher, Neville Hacker, Yunkai Gao, David Bowtell, Anna deFazio, Kylie L Gorringe
Low-grade serous ovarian carcinoma (LGSOC) is associated with a poor response to existing chemotherapy, highlighting the need to p..
The development and evaluation of a nationwide training program for oncology health professionals in the provision of genetic testing for ovarian cancer patients
M Gleeson, M Kentwell, B Meiser, J Do, S Nevin, N Taylor, K Barlow-Stewart, J Kirk, P James, CL Scott, R Williams, K Gamet, J Burke, M Murphy, YC Antill, A Pearn, N Pachter, C Ebzery, N Poplawski, M Friedlander
BACKGROUND: BRCA1/2 mutation status has increasing relevance for ovarian cancer treatments, making traditional coordination of gen..
Exome sequencing of familial high-grade serous ovarian carcinoma reveals heterogeneity for rare candidate susceptibility genes
Deepak N Subramanian, Magnus Zethoven, Simone McInerny, James A Morgan, Simone M Rowley, Jue Er Amanda Lee, Na Li, Kylie L Gorringe, Paul A James, Ian G Campbell
High-grade serous ovarian carcinoma (HGSOC) has a significant hereditary component, approximately half of which cannot be explaine..
Pooled Genomic Screens Identify Anti-apoptotic Genes as Targetable Mediators of Chemotherapy Resistance in Ovarian Cancer
Elizabeth H Stover, Maria B Baco, Ofir Cohen, Yvonne Y Li, Elizabeth L Christie, Mukta Bagul, Amy Goodale, Yenarae Lee, Sasha Pantel, Matthew G Rees, Guo Wei, Adam G Presser, Maya K Gelbard, Weiqun Zhang, Ioannis K Zervantonakis, Patrick D Bhola, Jeremy Ryan, Jennifer L Guerriero, Joan Montero, Felice J Liang
High-grade serous ovarian cancer (HGSOC) is often sensitive to initial treatment with platinum and taxane combination chemotherapy..
Evaluation of telephone genetic counselling to facilitate germline BRCA1/2 testing in women with high-grade serous ovarian cancer
Erin Tutty, Lara Petelin, Joanne McKinley, Mary-Anne Young, Bettina Meiser, Victoria M Rasmussen, Rowan Forbes Shepherd, Paul A James, Laura E Forrest
Systemic healthcare issues and geographical challenges restrict women's access to BRCA1/2 testing to inform the use of tailored tr..
Survival Following Chemotherapy in Ovarian Clear Cell Carcinoma Is Not Associated with Pathological Misclassification of Tumor Histotype
Masataka Takenaka, Martin Kobel, Dale W Garsed, Sian Fereday, Ahwan Pandey, Dariush Etemadmoghadam, Joy Hendley, Ayako Kawabata, Daito Noguchi, Nozomu Yanaihara, Hiroyuki Takahashi, Takako Kiyokawa, Masahiro Ikegami, Hirokuni Takano, Seiji Isonishi, Kazuhiko Ochiai, Nadia Traficante, Sreeja Gadipally, Timothy Semple, Dane Vassiliadis
PURPOSE: Although ovarian clear cell carcinomas (OCCC) are commonly resistant to platinum-based chemotherapy, good clinical outcom..
Going to extremes: determinants of extraordinary response and survival in patients with cancer
Flurina AM Saner, Alan Herschtal, Brad H Nelson, Anna deFazio, Ellen L Goode, Susan J Ramus, Ahwan Pandey, Jessica A Beach, Sian Fereday, Andrew Berchuck, Stephanie Lheureux, Celeste Leigh Pearce, Paul D Pharoah, Malcolm C Pike, Dale W Garsed, David DL Bowtell
Research into factors affecting treatment response or survival in patients with cancer frequently involves cohorts that span the m..
Population-based genetic testing of asymptomatic women for breast and ovarian cancer susceptibility
Simone M Rowley, Lyon Mascarenhas, Lisa Devereux, Na Li, Kaushalya C Amarasinghe, Magnus Zethoven, Jue Er Amanda Lee, Alexandra Lewis, James A Morgan, Sharpe Limb, Mary-Anne Young, Paul A James, Alison H Trainer, Ian G Campbell
PURPOSE: The identification of carriers of hereditary breast and ovarian cancer (HBOC) gene variants through family cancer history..
19q12 amplified and non-amplified subsets of high grade serous ovarian cancer with overexpression of cyclin E1 differ in their molecular drivers and clinical outcomes
Diar Aziz, Dariush Etemadmoghadam, C Elizabeth Caldon, George Au-Yeung, Niantao Deng, Ryan Hutchinson, David Bowtell, Paul Waring
OBJECTIVES: Readily apparent cyclin E1 expression occurs in 50% of HGSOC, but only half are linked to 19q12 locus amplification. T..
Long-term efficacy, tolerability and overall survival in patients with platinum-sensitive, recurrent high-grade serous ovarian cancer treated with maintenance olaparib capsules following response to chemotherapy
Michael Friedlander, Ursula Matulonis, Charlie Gourley, Andreas du Bois, Ignace Vergote, Gordon Rustin, Clare Scott, Werner Meier, Ronnie Shapira-Frommer, Tamar Safra, Daniela Matei, Vadim Shirinkin, Frederic Selle, Anitra Fielding, Elizabeth S Lowe, Emma L McMurtry, Stuart Spencer, Philip Rowe, Helen Mann, David Parry
BACKGROUND: In Study 19, maintenance monotherapy with olaparib significantly prolonged progression-free survival vs placebo in pat..
Association of p16 expression with prognosis varies across ovarian carcinoma histotypes: an Ovarian Tumor Tissue Analysis consortium study
Peter F Rambau, Robert A Vierkant, Maria P Intermaggio, Linda E Kelemen, Marc T Goodman, Esther Herpel, Paul D Pharoah, Stefan Kommoss, Mercedes Jimenez-Linan, Beth Y Karlan, Aleksandra Gentry-Maharaj, Usha Menon, Susanna Hernando Polo, Francisco J Candido dos Reis, Jennifer Anne Doherty, Simon A Gayther, Raghwa Sharma, Melissa C Larson, Paul R Harnett, Emma Hatfield
We aimed to validate the prognostic association of p16 expression in ovarian high-grade serous carcinomas (HGSC) and to explore it..
Does the primary site really matter? Profiling mucinous ovarian cancers of uncertain primary origin (MO-CUP) to personalise treatment and inform the design of clinical trials.
Nicola S Meagher, Klaus Schuster, Andreas Voss, Timothy Budden, Chi Nam Ignatius Pang, Anna deFazio, Susan J Ramus, Michael L Friedlander
OBJECTIVE: Advanced stage mucinous ovarian cancers are diagnostically and therapeutically challenging. Histotype specific trials h..